Business Context and Reporting Period
This Form 8-K was filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc.) on November 2, 2023. The registrant is a Delaware corporation with its principal executive offices in Alpharetta, GA. The company is an emerging growth company and its common stock trades on the Nasdaq Capital Market under the symbol "VIRI".
Key Financial Metrics
This filing is a current report regarding a listing status notice and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes
The material event reported is the receipt of a notice from Nasdaq on November 2, 2023, stating that the company's common stock bid price closed below the minimum $1.00 per share requirement for 30 consecutive business days. This constitutes a failure to satisfy Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Contingencies
- Compliance Period: The company has been granted an initial 180-day compliance period to regain compliance, ending on May 1, 2024 (noted as May 1, 2023 in the text, which is a likely typographical error given the filing date).
- Regaining Compliance: Compliance can be achieved if the bid price closes at $1.00 or more for 10 consecutive business days before the compliance date.
- Delisting Risk: If the company fails to regain compliance by the deadline, it may qualify for a second 180-day period. Failure to comply during the second period will result in a delisting notice.
- Appeal Process: The company may appeal a delisting determination to the Nasdaq Listing Qualifications Panel, though success is not assured.
- Management Action: Management intends to monitor the stock price and consider available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of VIRI stock to assess proximity to the $1.00 threshold.
- Confirm the exact compliance deadline date, noting the potential typo in the filing regarding the year (2023 vs 2024).
- Review subsequent filings for any announcements regarding reverse stock splits or other capital actions intended to restore compliance.
- Monitor for any further correspondence from Nasdaq regarding the extension of the compliance period or delisting notices.